AI assistant
Aclaris Therapeutics, Inc. — Director's Dealing 2021
Jun 3, 2021
33670_dirs_2021-06-02_ceb4b3e6-ff9d-489c-b055-ab352cf5cf07.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aclaris Therapeutics, Inc. (ACRS)
CIK: 0001557746
Period of Report: 2021-06-01
Reporting Person: Monahan Joseph (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-01 | Common Stock | M | 50000 | — | Acquired | 107132 | Direct |
| 2021-06-02 | Common Stock | S | 18240 | $21.5039 | Disposed | 88892 | Direct |
| 2021-06-02 | Common Stock | S | 3550 | $22.3114 | Disposed | 85342 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-01 | Restricted Stock Units | $ | M | 50000 | Disposed | Common Stock (50000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 193 | Indirect |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections.
F3: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.03 to $22.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.03 to $22.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The shares underlying these restricted stock units vested on June 1, 2021.